McGuire VA Medical Center

Summary

McGuire VA Medical Center is a medical facility located in Burke, Virginia. This center is recognized for care of Liver Cirrhosis, Fibrosing Colonopathy, Prostate Cancer, Spinal Cord Injury, Nonalcoholic Steatohepatitis and other specialties. McGuire VA Medical Center is involved with conducting 141 clinical trials across 309 conditions. There are 30 research doctors associated with this hospital, such as Jasmohan Bajaj, MD, Lance Goetz, MD, Michael Fuchs, MD, and Denise Lester, MD.

Top PIs

Clinical Trials running at McGuire VA Medical Center

Prostate Cancer

Spinal Cord Injury

Lung Cancer

Parkinson's Disease

Fibrosing Colonopathy

Cancer

Heart Failure

Post-Traumatic Stress Disorder

Liver Cirrhosis

Obsessive-Compulsive Disorder

Pembrolizumab

for Prostate Cancer

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.

Recruiting

2 awards

Phase 2

3 criteria

Systemic + Local Therapy

for Prostate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.

Recruiting

1 award

Phase 2 & 3

3 criteria